Neoleukin sends 70% of staff packing as IL-2 biotech searches for sale or other exit
Neoleukin Therapeutics is preparing to fold its cards and will cut 70% of its remaining staff, including the CEO, about half a year after ending …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
